Form 8-K - Current report:
SEC Accession No. 0001193125-26-267550
Filing Date
2026-06-11
Accepted
2026-06-11 16:12:52
Documents
12
Period of Report
2026-06-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ck0001657677-20260609.htm   iXBRL 8-K 77118
2 EX-3.1 ck0001657677-ex3_1.htm EX-3.1 76514
3 EX-3.2 ck0001657677-ex3_2.htm EX-3.2 216855
4 EX-10.1 ck0001657677-ex10_1.htm EX-10.1 86221
  Complete submission text file 0001193125-26-267550.txt   639186

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001657677-20260609.xsd EX-101.SCH 28040
15 EXTRACTED XBRL INSTANCE DOCUMENT ck0001657677-20260609_htm.xml XML 5098
Mailing Address 30 ACORN PARK DRIVE 6TH FLOOR CAMBRIDGE MA 02140
Business Address 30 ACORN PARK DRIVE 6TH FLOOR CAMBRIDGE MA 02140 617-945-9510
Parabilis Medicines, Inc. (Filer) CIK: 0001657677 (see all company filings)

EIN.: 474505725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-43331 | Film No.: 261083157
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)